Mortality in rheumatoid arthritis: 2008 update

Clinical and Experimental Rheumatology

Volumn 26, Issue 5 SUPPL. 51, 2008, Pages

  Sokka, Tuulikki ^a,b,c   Abelson, Benjamin ^d   Pincus, Theodore ^d,e  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^c Finland MedCare Ltd   (Finland)

^d NYU HOSPITAL FOR JOINT DISEASES   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Causes of death; Mortality; Prognostic markers; Rheumatoid arthritis; Standard mortality ratios

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUCOCORTICOID; GOLD SALT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; JOINT RADIOGRAPHY; KIDNEY DISEASE; LOW DRUG DOSE; LUNG DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDLINE; MORTALITY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHYSICAL DISABILITY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX RATIO; SOCIAL STATUS; SURVIVAL RATE;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CAUSE OF DEATH; COMORBIDITY; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 55349118821     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (221)

1. COBB S, ANDERSON F, BAUER W: Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953; 249: 553-6.
2. REAH TG: The prognosis of rheumatoid arthritis (185 patients followed up over 13 years). Proc R Soc Med 1963; 56: 813-7.
3. DUTHIE JJR, BROWN PE, TRUELOVE LH, BARAGAR FD, LAWRIE AJ: Course and prognosis in rheumatoid arthritis: a further report. Ann Rheum Dis 1964; 23: 193-204.
4. UDDIN J, KRAUS AS, KELLY HG: Survivorship and death in rheumatoid arthritis. Arthritis Rheum 1970; 13: 125-30.
5. JACOBY RK, JAYSON MIV, COSH JA: Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973; 2: 96-100.
6. RASKER JJ, COSH JA: Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis 1981; 40: 115-20.
7. COSH JA, RASKER JJ: A 20-year follow-up of 100 patients with rheumatoid arthritis (RA). Ann Rheum Dis 1982; 41: 317.
8. RASKER JJ, COSH JA: The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol 1984; 3: 11-20.
9. RASKER JJ, COSH JA: The natural history of rheumatoid arthritis over 20 years. Clinical symptoms, radiological signs, treatment, mortality and prognostic significance of early features. Clin Rheumatol 1987; 6 (Suppl. 2): 5-11.
10. REILLY PA, COSH JA, MADDISON PJ, RASKER JJ, SILMAN AJ: Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-9.
11. MINAUR NJ, JACOBY RK, COSH JA, TAYLOR G, RASKER JJ: Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol 2004; 31(S69): 3-8.
12. GORDON DA, STEIN JL, BRODER I: The extra-articular features of rheumatoid arthritis: a systematic analysis of 127 cases. Am J Med 1973; 54: 445-52.
13. ISOMÄKI HA, MUTRU O, KOOTA K: Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 1975; 4: 205-8.
14. KOOTA K, ISOMÄKI H, MUTRU O: Death rate and causes of death in RA patients during a period of five years. Scand J Rheumatol 1977; 6: 241-4.
15. MUTRU O, LAAKSO M, ISOMÄKI H, KOOTA K: Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J 1985; 290: 1797-99.
16. LAAKSO M, MUTRU O, ISOMÄKI H, KOOTA K: Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1986; 13: 522-6.
17. LAAKSO M, ISOMÄKI HA, MUTRU O,KOOTA K: Death certificate and mortality in rheumatoid arthritis. Scand J Rheumatol 1986; 15: 129-33.
18. LAAKSO M, MUTRU O, ISOMAKI H, KOOTA K: Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis. Ann Rheum Dis 1986; 45: 663-7.
19. MUTRU O, LAAKSO M, ISOMÄKI H, KOOTA K: Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76: 71-7.
20. MONSON RR, HALL AP: Mortality among arthritics. J Chron Dis 1976; 29: 459-67.
21. FLEMING A, CROWN JM, CORBETT M: Prognostic value of early features in rheumatoid disease. Br Med J 1976; 1: 1243-5.
22. CORBETT M, DALTON S, YOUNG A, SILMAN A, SHIPLEY M: Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993; 32: 717-23.
23. LEWIS P, HAZLEMAN BL, HANKA R, ROBERTS S: Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis 1980; 39: 457-61.
24. LINOS A, WORTHINGTON JW, O'FALLON WM, KURLAND LT: The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111: 87-98.
25. ALLEBECK P, AHLBOM A, ALLANDER E: Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate: eleven year follow-up of an epidemiological study. Scand J Rheumatol 1981; 10: 301-6.
26. ALLEBECK P, RODVALL Y, ALLANDER E: Mortality in rheumatoid arthritis, particularly as regards drug use. Scand J Rheumatol 1985; 14: 102-8.
27. ALLEBECK P: Increased mortality in rheumatoid arthritis. Scand J Rheumatol 1982; 11: 81-6.
28. SCOTT DL, COULTON BL, CHAPMAN JH, BACON PA, POPERT AJ: The long-term effects of treating rheumatoid arthritis. J R Coll Physicians Lond 1983; 17: 79-85.
29. FOSTER CS, FORSTOT SL, WILSON LA: Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91: 1253-63.
30. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
31. PINCUS T, CALLAHAN LF: Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chronic Dis 1985; 38: 973-84.
32. PINCUS T, CALLAHAN LF, VAUGHN WK: Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987; 14: 240-51.
33. PINCUS T, BROOKS RH, CALLAHAN LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34.
34. PRIOR P, SYMMONS DPM, SCOTT DL, BROWN R, HAWKINS CF: Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92-9.
35. SYMMONS DPM, PRIOR P, SCOTT DL, BROWN R, HAWKINS CF: Factors influencing mortality in rheumatoid arthritis. J Chronic Dis 1986; 39: 137-45.
36. SYMMONS DP, JONES MA, SCOTT DL, PRIOR P: Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol 1998; 25: 1072-7.
37. VANDENBROUCKE JP, HAZEVOET HM, CATS A: Survival and cause of death in rheumatoid arthritis: A 25-year prospective followup. J Rheumatol 1984; 11: 158-61.
38. MITCHELL DM, SPITZ PW, YOUNG DY, BLOCH DA, MCSHANE DJ, FRIES JF: Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-14.
39. FRIES J, BLOCH D, SPITZ P: Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med 1985; 78: 56-9.
40. WICKS IP, MOORE J, FLEMING A: Australian mortality statistics for rheumatoid arthritis 1950-81: analysis of death certificate data. Ann Rheum Dis 1988; 47: 563-9.
41. WOLFE F, KLEINHEKSEL SM, CATHEY MA, HAWLEY DJ, SPITZ PW, FRIES JF: The clinical value of the Stanford health assessment questionnaire functional disability Index in patients with rheumatoid arthritis. J Rheumatol 1988; 15: 1480-8.
42. ERHARDT CC, MUMFORD PA, VENABLES PJW, MAINI RN: Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7-13.
43. SAWAY PA, BLACKBURN WD, HALLA JT, ALARCÓN GS: Clinical characteristics affecting survival in patients with rheumatoid arthritis undergoing cervical spine surgery: a controlled study. J Rheumatol 1989; 16: 890-6.
44. KAZIS LE, ANDERSON JJ, MEENAN RF: Health status as a predictor of mortality in rheumatoid arthritis: a five-year study. J Rheumatol 1990; 17: 609-13.
45. LEHTINEN K, ISOMÄKI H: Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. J Rheumatol 1991; 18: 524-9.
46. LEIGH JP, FRIES JF: Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991; 18: 1307-12.
47. JACOBSSON LT, KNOWLER WC, PILLEMER S et al.: Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 1993; 36: 1045-53.
48. WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
49. COSTE J, JOUGLA E: Mortality from rheumatoid arthritis in France, 1970-1990. Int J Epidemiol 1994; 23: 545-52.
50. RADIS CD, KAHL LE, BAKER GL et al.: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38: 1120-7.
51. MYLLYKANGAS-LUOSUJÄRVI R, AHO K, KAUTIAINEN H, ISOMÄKI H: Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 149-53.
52. MYLLYKANGAS-LUOSUJARVI R, AHO K, KAUTIAINEN H, ISOMAKI H: Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995; 22: 1065-7.
53. MYLLYKANGAS-LUOSUJARVI R, AHO K, ISOMAKI H: Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol 1995; 24: 76-8.
54. NEVA MH, MYLLYKANGAS-LUOSUJARVI R, KAUTIAINEN H, KAUPPI M: Mortality associated with cervical spine disorders: a population-based study of 1666 patients with rheumatoid arthritis who died in Finland in 1989. Rheumatology (Oxford) 2001; 40: 123-7.
55. HELIÖVAARA M, AHO K, KNEKT P, AROMAA A, MAATELA J, REUNANEN A: Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis 1995; 54: 811-4.
56. JONES M, SYMMONS D, FINN J, WOLFE F: Does exposure to immumosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35: 738-45.
57. VOSKUYL AE, ZWINDERMAN AH, WESTEDT ML, VANDERBROUCKE JP, BREEDVELD FC, HAZES JMW: The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996; 39: 266-71.
58. CALLAHAN LF, CORDRAY DS, WELLS G, PINCUS T: Formal education and five-year mortality in rheumatoid arthritis: Mediation by helplessness scale scores. Arthritis Care Res 1996; 9: 463-72.
59. PINCUS T, KEYSOR J, SOKKA T, KRISHNAN E, CALLAHAN LF: Patient questionnaires and formal education level as prospective predictors of mortality over 10 years in 97% of 1416 patients with rheumatoid arthritis from 15 United States private practices. J Rheumatol 2004; 31: 229-34.
60. SWINSON DR, SYMMONS D, SURESH U, JONES M, BOOTH J: Decreased survival in patients with co-exist rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997; 36: 689-91.
61. CALLAHAN LF, PINCUS T, HUSTON JW, III, BROOKS RH, NANCE EP, JR., KAYE JJ: Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997; 10: 381-94.
62. KREMER JM: Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years. Arthritis Rheum 1997; 40: 984-5.
63. WALLBERG-JONSSON S, OHMAN ML, DAHLQVIST SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51.
64. SÖDERLIN MK, NIEMINEN P, HAKALA M: Functional status predicts mortality in a community based rheumatoid arthritis population, J Rheumatol 1998; 25: 1895-9.
65. VAN DEN BORNE BE, LANDEWÉ RB, HOUKES I et al.: No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1930-7.
66. LINDQVIST E, EBERHARDT K: Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999; 58: 11-4.
67. TURESSON C, JACOBSSON L, BERGSTROM U: Extra-articular rheumatoid arthritis: Prevalence and mortality. Rheumatology 1999; 38: 668-74.
68. SOKKA T, MÖTTÖNEN T, HANNONEN P: Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. Scand J Rheumatol 1999; 28: 282-7.
69. GABRIEL SE, CROWSON CS, O'FALLON M: Mortality in rheumatoid arthritis: Have we made an impact in 4 decades? J Rheumatol 1999; 26: 2529-33.
70. MAIDEN N, CAPELL HA, MADHOK R, HAMPSON R, THOMSON EA: Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis 1999; 58: 525-9.
71. WALLBERG-JONSSON S, JOHANSSON H, OHMAN ML, RANTAPAA-DAHLQVIST S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-71.
72. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14-21.
73. KVALVIK AG, JONES MA, SYMMONS DPM: Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 29-37.
74. KROOT EJ, VAN LEEUWEN MA, VAN RIJSWIJK MH et al.: No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000; 59: 954-8.
75. RIISE T, JACOBSEN BK, GRAN JT, HAGA HJ, ARNESEN E: Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 2001; 20: 123-7.
76. CHEHATA JC, HASSELL AB, CLARKE SA et al.: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology 2001; 40: 447-52.
77. ISAACS JD, GREER S, SHARMA S et al.: Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001; 44: 1998-2008.
78. LORENZI AR, CLARKE AM, WOOLDRIDGE T et al.: Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum 2008; 58: 370-5.
79. MARTÍNEZ MS, GARCÍA-MONFORTE A, RIVERA J: Survival study of rheumatoid arthritis patients in Madrid (spain). A 9-year prospective follow-up. Scand J Rheumatol 2001; 30: 195-8.
80. RIISE T, JACOBSEN BK, GRAN JT: High mortality in patients with rheumatoid arthritis and atlantoaxial subluxation. J Rheumatol 2001; 28: 2425-9.
81. UHRIN Z, WANG BW, MATSUDA Y, STROBER S, GENOVESE MC: Treatment of rheumatoid arthritis with total lymphoid irradiation: long-term survival. Arthritis Rheum 2001; 44: 1525-8.
82. CHEVREL G, JENVRIN C, MCGREGOR B, MIOSSEC P: Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology 2001; 40: 821-5.
83. DORAN MF, POND GR, CROWSON CS, O'FALLON WM, GABRIEL SE: Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46: 625-31.
84. GABRIEL SE, CROWSON CS, KREMERS HM et al.: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8.
85. TURESSON C, O'FALLON WM, CROWSON CS, GABRIEL SE, MATTESON EL: Occurence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62-7.
86. KREMERS HM, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3450-7.
87. KREMERS HM, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.
88. MARADIT KREMERS H, CROWSON CS, NICOLA PJ et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
89. NICOLA PJ, CROWSON CS, MARADIT-KREMERS H et al.: Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006; 54: 60-7.
90. YELIN E, TRUPIN L, WONG B, RUSH S: The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002; 29: 1851-7.
91. CHOI HK, HERNÁN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
92. BJORNADAL L, BAECKLUND E, YIN L, GRANATH F, KLARESKOG L, EKBOM A: Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002; 29: 906-12.
93. MIKULS TR, SAAG KG, CRISWELL LA et al.: Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002; 61: 994-9.
94. PELTOMAA R, PAIMELA L, KAUTIAINEN H, LEIRISALO-REPO M: Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 2002; 61: 889-94.
95. GOODSON NJ, WILES NJ, LUNT M, BARRETT EM, SILMAN AJ, SYMMONS DPM: Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010-9.
96. FARRAGHER TM, LUNT M, BUNN DK, SILMAN AJ, SYMMONS DP: Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007; 66: 486-92.
97. FARRAGHER TM, GOODSON NJ, NASEEM H et al.: Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58: 359-69.
98. NAZ SM, FARRAGHER TM, BUNN DK, SYMMONS DP, BRUCE IN: The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008; 58: 985-9.
99. WATSON DJ, RHODES T, GUESS HA: All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196-202.
100. NAVARRO-CANO G, DEL RINCÓN I, POGOSIAN S, ROLDÁN JF, ESCALANTE A: Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003; 48: 2425-33.
101. THOMAS E, SYMMONS DP, BREWSTER DH, BLACK RJ, MACFARLANE GJ: National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003; 30: 958-65.
102. WOLFE F, MICHAUD K, GEFELLER O, CHOI HK: Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1530-42.
103. ANG DC, CHOI H, KROENKE K, WOLFE F: Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1013-9.
104. SOLOMON DH, KARLSON EW, RIMM EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
105. SIHVONEN S, KORPELA M, MUSTONEN J, LAIPPALA P, PASTERNACK A: Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract 2004; 96: c107-14.
106. SIHVONEN S, KORPELA M, MUSTILA A, MUSTONEN J: The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 2089-94.
107. SIHVONEN S, KORPELA M, MUSTONEN J, HUHTALA H, KARSTILA K, PASTERNACK A: Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 2006; 33: 1740-6.
108. KRISHNAN E, LINGALA VB, SINGH G: Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004; 110: 1774-9.
109. SOKKA T, HAKKINEN A, KRISHNAN E, HANNONEN P: Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004; 63: 494-7.
110. KAUPPI M, SOKKA T, HANNONEN P: Survey nonresponse is associated with increased mortality in patients with rheumatoid arthritis and in a community population. J Rheumatol 2005; 32: 807-10.
111. BOOK C, SAXNE T, JACOBSSON LTH: Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol 2005; 32: 430-4.
112. GOODSON N, MARKS J, LUNT M, SYMMONS D: Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-601.
113. HAKODA M, OIWA H, KASAGI F et al.: Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. Ann Rheum Dis 2005; 64: 1451-5.
114. ESCALANTE A, HAAS RW, DEL RINCÓN I: Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165: 1624-9.
115. RONKAINEN A, NISKANEN M, AUVINEN A, AALTO J, LUOSUJARVI R: Cervical spine surgery in patients with rheumatoid arthritis: longterm mortality and its determinants. J Rheumatol 2006; 33: 517-22.
116. CARMONA L, DESCALZO, MA, PEREZ-PAMPIN E et al.: All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-5.
117. ABÁSOLO L, JÚDEZ E, DESCALZO, MA et al.: Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2007; 37: 388-97.
118. JACOBSSON LT, TURESSON C, NILSSON JA et al.: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670-5.
119. GONZALEZ A, MARADIT KREMERS H, CROWSON CS et al.: The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7.
120. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ Mi et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
121. YOUNG A, KODURI G, BATLEY M et al.: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007; 46: 350-7.
122. MATTEY DL, THOMSON W, OLLIER WE et al.: Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007; 56: 1408-16.
123. MATTEY DL, GLOSSOP JR, NIXON NB, DAWES PT: Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3940-8.
124. NIKOLAISEN C, FIGENSCHAU Y, NOSSENT JC: Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008; 35: 380-6.
125. SOKKA T, KAUTIAINEN H, HANNONEN P, PINCUS T: Changes in health assessment questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum 2006; 54: 3113-8.
126. AVALOS T, RHO YH, CHUNG CP, STEIN CM: Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S5-S13.
127. PINCUS T, CALLAHAN LF: Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841-5.
128. PINCUS T, CALLAHAN LF: Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989; 18 (Suppl. 79): 67-96.
129. PINCUS T, CALLAHAN LF: The 'side effects' of rheumatoid arthritis: Joint destruction, disability and early mortality. Br J Rheumatol 1993; 32: (Suppl.1): 28-37.
130. CALLAHAN LF, PINCUS T: Mortality in rheumatic diseases. Arthritis Care Res 1995; 8: 229-41.
131. PINCUS T, SOKKA T: Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses? J Rheumatol 2001; 28: 1723-34.
132. SOKKA T, HAUGEBERG G, PINCUS T: Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective. Clin Exp Rheumatol 2007; 25 (Suppl. 47): 86-97.
133. LINDAHL BI, ALLANDER E: Problems in the classification of cause of death diagnoses affecting the reliability of mortality statistics for rheumatoid arthritis. J Chronic Dis 1985; 38: 409-18.
134. SYMMONS DP: Mortality in rheumatoid arthritis. Br J Rheumatol 1988; 27: 44-54.
135. MYLLYKANGAS-LUOSUJÄRVI RA, AHO K, ISOMÄKI HA: Mortality in rheumatoid arthritis. Semin Arthritis Rheum 1995; 25: 193-202.
136. WARD MM: Recent improvements in survival in patients with rheumatoid arthritis: Better outcomes or different study designs? Arthritis Rheum 2001; 44: 1467-9.
137. DIXON WG, SYMMONS DP: What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66: 1132-6.
138. AKHAVANI MA, LARSEN H, PALEOLOG E: Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. Scand J Rheumatol 2007; 36: 83-90.
139. NAZ SM, SYMMONS DP: Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 871-83.
140. WOLFE F, PINCUS T: Listening to the patient: A practical guide to self-report questionnaires in clinical care. Arthritis Rheum 1999; 42: 1797-808.
141. PINCUS T: Documenting quality management in rheumatic disease: Are patient questionnaires the best (and only) method? Arthritis Care Res 1996; 9: 339-48.
142. JOINT NATIONAL COMMITTEE ON PREVENTION DEATOHBP, NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM COOR'DINATING COMMITTEE: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
143. AMERICAN DIABETES ASSOCIATION: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000; 23: S32-S42.
144. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73.
145. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T et al.: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 36-41.
146. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
147. GOEKOOP-RUITERMAN YPM, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
148. GOEKOOP-RUITERMAN YPM, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146: 406-15.
149. VERSTAPPEN SMM, JACOBS JWG, VAN DER VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
150. HETLAND ML, STENGAARD-PEDERSEN K, JUNKER P et al.: Aggressive combination therapy with intraarticular glucocorticoid injections and conventional DMARDs in early rheumatoid arthritis Two Year Clinical and Radiographic Results From The CIMESTRA Study. Ann Rheum Dis 2007. Ref Type: Abstract
151. HETLAND ML, EJBJERG BJ, HORSLEV-PETERSEN K et al.: MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA). Ann Rheum Dis 2008; Apr 3 [Epub ahead of print].
152. HETLAND ML, STENGAARD-PEDERSEN K, JUNKER P et al.: Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67: 815-22.
153. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
154. TUGWELL P, BOERS M: OMERACT Committee. Proceedings of the OMERACT Conferences on outcome measures in rheumatoid arthritis clinical trials, Maastrict, Netherlands. J Rheumatol 1993; 20: 527-91.
155. VAN RIEL PLCM: Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis (Editorial). Br J Rheumatol 1992; 31: 793-4.
156. BOERS M, TUGWELL P, FELSON DT et al.: World Health Organization and International League ofAssociations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21 (Suppl. 41): 86-9.
157. PINALS RS, MASI AT, LARSEN RA et al.: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
158. SOKKA T, MAKINEN H, HANNONEN P, PINCUS T: Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1020-3.
159. WOLFE F, HAWLEY DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-52.
160. MAKINEN H, HANNONEN P, SOKKA T: Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomized clinical trials for the rate of remission. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S22-S28.
161. VAN DER HEIJDE DMFM, VAN'T HOF MA, VAN RIEL PLCM et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
162. VAN DER HEIJDE DMFM, VAN'T HOF M, VAN RIEL PLCM, VAN DE PUTTE LBA: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
163. FRANSEN J, VAN RIEL PLCM: DAS remission cut points. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S29-S32.
164. ALETAHA D, SMOLEN J: The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S100-S108.
165. ALETAHA D, WARD MM, MACHOLD KP, NELL VP, STAMM T, SMOLEN is: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
166. PINCUS T, BERGMAN MJ, YAZICI Y, HINES P, RAGHUPATHI K, MACLEAN R: An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAP-ID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008; 47: 345-9.
167. PINCUS T, SWEARINGEN CJ, BERGMAN M, YAZICI Y: RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. J Rheumatol 2008; in press.
168. PINCUS T, KAVANAUGH A, ALETAHA D, SMOLEN J: Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S1-S6.
169. SINGER RB: Mortality in rheumatoid arthritis: experience in four clinical series compared with the experience in the 1983 medical impairment study. J Insur Med 1998; 30: 88-95.
170. MATTESON EL, WEYAND CM, FULBRIGHT JW, CHRISTIANSON TJH, MCCLELLAND RL, GORONZY JJ: How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial. Rheumatology 2004; 43: 619-25.
171. WONG JB, RAMEY DR, SINGH G: Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2746-9.
172. PINCUS T, GIBOFSKY A, WEINBLATT ME: Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002; 46: 851-4.
173. NISHIMURA K, SUGIYAMA D, KOGATA Y et al.: Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808.
174. WOLFE F, MICHAUD K: The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994; 21: 1227-37.
175. ROPES MW, BENNETT GA, COBB S, JACOX RF, JESSAR RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175-6.
176. O'SULLIVAN JB, CATHCART ES: The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 1972; 76: 573-7.
177. MIKKELSEN WM, DODGE H: A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, community health study. Arthritis Rheum 1969; 12: 87-91.
178. LICHTENSTEIN MJ, PINCUS T: Rheumatoid arthritis identified in population based cross sectional studies: Low prevalence of rheumatoid factor. J Rheumatol 1991; 18: 989-93.
179. VALKENBERG HA, BALL J, BURCH TA, BENNETT PH, LAWRENCE JS: Rheumatoid factors in a rural population. Ann Rheum Dis 1966; 25: 497-507.
180. MIKKELSEN WM, DODGE HJ, DUFF IF, KATO H: Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. J Chronic Dis 1967; 20: 351-69.
181. ADLER E, ABRAMSON JH, GOLDBERG R, ELKAN Z, BEN HADOR S: Rheumatoid arthritis in a Jerusalem population: 2. Epidemiology of rheumatoid factors. Am J Epidemiol 1967; 85: 378-86.
182. BURCH TA, O'BRIEN WM, LAWRENCE JS, BENNETT PH, BUNIM JJ: A comparison of the prevalence of rheumatoid arthritis (R.A.) and rheumatoid factor (R.F.) in Indian tribes living in Montana mountains and in Arizona desert. Arthritis Rheuma 1963; 6: 765.
183. AHO K, JULKUNEN H, LAINE V, RIPATTI N, WAGER O: Clinical evaluation of the serological tests in rheumatoid arthritis. 1. Normal series collected by random sampling. Acta Rheumatol Scand 1961; 7: 201-8.
184. SOKKAT, PINCUS T: A historical perspective concerning population-based and clinical studies of early arthritis and early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: S5-S14.
185. VAN DER HORST-BRUINSMA IE, SPEYER I, VISSER H, BREEDVELD FC, HAZES JMW: Diagnosis and course of early-onset arthritis: Results of a special early arthritis clinic compared to routine patient care. Br J Rheamatol 1998; 37: 1084-8.
186. VAN AKEN J, VAN BILSEN JHM, ALLAART CF, HUIZINGA TWJ, BREEDVELD FC: The Leiden Early Arthritis Clinic. Clin Exp Rheumatol 2003; 21: S100-S105.
187. MACHOLD KP, NELL VPK, STAMM TA, EBERL G, STEINER G, SMOLEN is: The Austrian Early Arthritis Registry. Clin Exp Rheumatol 2003; 21: S113-S117.
188. SOKKA T, KAUTIAINEN H, TOLOZA S et al.: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007; 66: 1491-6.
189. CALLAHAN LF, SMITH WJ, PINCUS T: Self-report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989; 2: 122-31.
190. SOKKA T, PINCUS T: Improved outcomes in consecutive patients with rheumatoid arthritis in 2000 compared to 1985, according to an identical cross sectional quantitative standard protocol to evaluate rheumatoid arthritis (SPERA). Arthritis Rheum 2002; 46: S242.
191. SOKKA T, PINCUS T: Ascendancy of weekly low-dose methourexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008; Aug 7. [Epub ahead of print].
192. SILMAN AJ: The changing face of rheumatoid arthritis: why the decline in incidence? Arthritis Rheum 2002; 46: 579-81.
193. GERBER Y, JACOBSEN SJ, FRYE RL, WESTON SA, KILLIAN JM, ROGER VL: Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation 2006; 113: 2285-92.
194. PINCUS T, YAZICI Y, BERGMAN M, MACLEAN R, HARRINGTON T: A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007; 21: 789-804.
195. PINCUS T, SOKKA T: Should an order to "monitor long-term vital signs," including mortality outcomes, be as routine as an order for a laboratory test in patients with rheumatic diseases? Clin Exp Rheumatol 2008; 26 (Suppl. 51): S21-S24.
196. VETERANS ADMINISTRATION COOPERATIVE STUDY ON ANTIHYPERTENSIVE AGENT: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213: 1143-50.
197. ROSS SD, ALLEN IE, CONNELLY JE et al.: Clinical outcomes in statin treatment trials. Arch Intern Med 1999; 159: 1793-802.
198. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
199. STEIN CM, PINCUS T: Placebo-controlled studies in rheumatoid arthritis: Ethical issues. Lancet 1999; 353: 400-3.
200. GOODSON NJ, SYMMONS DP, SCOTT DG, BUNN D, LUNT M, SILMAN AJ: Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-9.
201. ASKLING J, FORED CM, BAECKLUND E et al.: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20.
202. ASKLING J, FORED CM, BRANDT L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6.
203. THOMAS E, BREWSTER DH, BLACK RJ, MACFARLANE GJ: Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497-502.
204. CARSTAIRS V, MORRIS R: Deprivation: explaining differences in mortality between Scotland and England and Wales. Br Med J 1989; 299: 886-9.
205. ABELSON B, RUPEL A, PINCUS T: Limitations of a biomedical model to explain socioeconomic disparities in mortality of rheumatic and cardiovascular diseases. Clin Exp Rheumatol 2008; 26 (Suppl. 51) S25-S34.
206. PINCUS T, CALLAHAN LF, BROOKS RH, FUCHS HA, OLSEN NJ, KAYE JJ: Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989; 110: 259-66.
207. OLSEN NJ, CALLAHAN LF, BROOKS RH et al.: Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am J Med 1988; 84: 257-64.
208. WEYAND CM, HICOK KC, CONN DL, GORONZY JJ: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801-6.
209. OLLIER W, VENABLES PJW, MUMFORD PA et al.: HLA antigen associations with extra-articular rheumatoid arthritis. Tissue Antigens 1984; 24: 279-91.
210. FUCHS HA, BROOKS RH, CALLAHAN LF, PINCUS T: A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989; 32: 531-7.
211. MULHERIN D, FITZGERALD O, BRESNIHAN B: Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996; 35: 1263-8.
212. PINCUS T, CALLAHAN LF: Rheumatology Function Tests: Grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol 1992; 19: 1051-7.
213. PINCUS T: Rheumatology function tests: quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases. Clin Exp Rheumatol 2005; 23: S85-S89.
214. TUGWELL P, WELLS G, STRAND V et al.: Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43: 506-14.
215. PINCUS T, AMARA I, SEGURADO OG, BERGMAN M, KOCH GG: Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2008; 35: 201-5.
216. WOLFE F, CATHEY MA, KLEINHEKSEL SM: Fibrositis (fibromyalgia) in rheumatoid arthritis. J Rheumatol 1984; 11: 814-8.
217. MYLLYKANGAS-LUOSUJÄRVI R, AHO K, ISOMÄKI H: Death attributed to antirheumatic medication in a nationwide geries of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995; 22: 2214-7.
218. WASSENBERG S, RAU R, STEINFELD P, ZEIDLER H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-80.
219. BUTTGEREIT F, SAAG KG, CUTOLO M, DA SILVA JAP, BIJLSMA JWJ: The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scan J Rheumatol 2005; 34: 14-21.
220. SVENSSON B, BOONEN A, ALBERTSSON K, VAN DER FIELIDE D, KELLER C, HAFSTROM I: Low-dose prednisolone in addition to the intial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52: 3360-70.
221. LUUKKAINEN R, ISOMÄKI H, KAJANDER A: Effect of gold treatment on the progression of erosions in RA patients. Scand J Rheumatol 1977; 6: 123-7.